The Children's Hospital Boston has selected Febit's Hybselect technology to enable genetics researchers to conduct the highly economic targeted enrichment of genes of interest for resequencing.
The Molecular Genetics Core Facility (MGCF) at the hospital will be receiving the Geniom RT analyser from Febit to perform Hybselect.
'The flexibility of Hybselect allows us to study a variety of genetic diseases and multiplex barcode libraries, making sequence capture projects much more accessible and affordable for our investigators,' said Hal Schneider, core manager of the MGCF.
The economy of Hybselect is said to increase the potential for widespread use of next-generation sequencing in clinical studies.
Instead of sequencing the complete genomes of only a few patients, Hybselect enables the analysis of specific genes of interest from large patient cohorts for the same price and data management effort.
The larger patient pool now provides the statistically relevant data necessary for clinical studies.
'Together with Life Technologies' Solid 3, Hybselect can sequence 16 parallel samples in one run,' said Peer Staehler, chief scientific officer at Febit.
'Febit is currently working on an upgrade to a 96-plex barcode set.
'This will enable sequencing of 2,304 samples in six working days,' he added.
